Members and their providers will need to consult the member's benefit plan to determine if there are any exclusions or other benefit limitations applicable to this service or supply. Members should discuss any matters related to their coverage or condition with their treating provider.Įach benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Treating providers are solely responsible for medical advice and treatment of members. The ABA Medical Necessity Guide does not constitute medical advice. The Applied Behavior Analysis (ABA) Medical Necessity Guide helps determine appropriate (medically necessary) levels and types of care for patients in need of evaluation and treatment for behavioral health conditions. Please see Aimovig ® full Prescribing Information.By clicking on “I Accept”, I acknowledge and accept that: Monitor patients treated with Aimovig ® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig ® is warranted if evaluation fails to establish an alternative etiology.Īdverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig ®-treated patients and more often than placebo) were injection site reactions and constipation. Aimovig ® was discontinued in many of the reported cases. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Many of the patients had pre-existing hypertension or risk factors for hypertension. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig ® in the postmarketing setting. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications. Monitor patients treated with Aimovig ® for severe constipation and manage as clinically appropriate. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies. Aimovig ® was discontinued in most reported cases. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. There were cases that required hospitalization, including cases where surgery was necessary. If a serious or severe reaction occurs, discontinue Aimovig ® and initiate appropriate therapy.Ĭonstipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig ® in the postmarketing setting. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig ® in post marketing experience. Reactions have included anaphylaxis and angioedema. Important Safety InformationĬontraindication: Aimovig ® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Aimovig ® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |